Brenez D, Devriendt J, Lenclud C, Schmerber J
Service de Médecine Interne, Hôpital Universitaire Brugmann (Université Libre de Bruxelles), Belgium.
Cancer Chemother Pharmacol. 1990;26(3):235-6. doi: 10.1007/BF02897207.
A case of acute nonlymphocytic leukemia (ANLL) following chemotherapy with cisplatin (CDDP) and etoposide (VP16) for non-small-cell lung cancer (NSCLC) diagnosed 24 months before is reported. Although the fortuitous occurrence of two unrelated malignancies cannot be excluded, the hypothesis of secondary leukemia must be taken into account. The clinical and experimental data implying these agents, generally considered to be noncarcinogenic in man, in the occurrence of secondary malignancies are briefly discussed.
报告了1例在24个月前被诊断为非小细胞肺癌(NSCLC)并接受顺铂(CDDP)和依托泊苷(VP16)化疗后发生急性非淋巴细胞白血病(ANLL)的病例。尽管不能排除两种不相关恶性肿瘤偶然发生的可能性,但必须考虑继发性白血病的假说。本文简要讨论了提示这些通常被认为对人类无致癌性的药物与继发性恶性肿瘤发生相关的临床和实验数据。